Last updated on January 2020

A Study to Assess the Antitumor Activity and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive Metastatic Pancreatic Adenocarcinoma

Brief description of study

The purpose of this study is to confirm the recommended phase 2 dose (RP2D) of zolbetuximab in combination with Nab-P + GEM, determine overall survival and assess the safety and tolerability of the combination treatment.

This study will also evaluate other anti-tumor effects, tumor markers and pharmacokinetics (PK) of zolbetuximab, Nab-P and GEM.

Detailed Study Description

This study will have a safety lead in phase and a randomization phase.

Clinical Study Identifier: NCT03816163

Find a site near you

Start Over

Site JP81006

Yokohama, Japan
  Connect »

Site JP81006

Yokohama-shi, Japan
  Connect »